Adding Relacorilant to Nab-paclitaxel Prolongs OS in Patients with Platinum-Resistant Ovarian Cancer By Ogkologos - April 21, 2026 4 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ROSELLA study Source RELATED ARTICLESMORE FROM AUTHOR Quadruplet Isa-KRd Regimen Improves NGS-MRD Negativity in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma EMA Recommends Granting a Marketing Authorisation for Tarlatamab Transdermal Oestradiol Patches Non-inferior to LHRH Agonists Regarding Metastasis-Free Survival in Patients with Locally Advanced Prostate Cancer MOST POPULAR EMA Recommends Granting a Marketing Authorisation for Fruquintinib May 13, 2024 Perguntas frequentes sobre COVID-19 e câncer: respostas para pacientes e sobreviventes June 23, 2020 Lazertinib Demonstrates Significant Efficacy Improvement Compared with Gefitinib in the First-Line... July 17, 2023 New Research Discovers How Scalp Cooling Helps Chemo Patients Keep Their... February 6, 2021 Load more HOT NEWS Man Who Lost His Leg Teaches Martial Arts To Orphans Of... When Both Tumour-Infiltrating Lymphocytes and Gene Expression are Available, the Prognostic... Foodie Fridays: Apple Bok Choy Salad Artificial Intelligence May Aid in the Discrimination of Radiation Pneumonitis from...
